We are here to extend our lives by THINKING DIFFERENT

Tuesday, January 19, 2010

Vertex Studies Timeline

On January 10, Vertex said that the VX-770 Phase 3 registration program is advancing rapidly, and it expects to obtain Phase 3 data for VX-770 early in 2011.

Additionally, Vertex also expects to obtain clinical data from a Phase 2 trial of VX-809 in the coming weeks that could potentially support the evaluation of VX-770 and VX-809 as part of a combination regimen in patients with the most common mutation of this disease.

No comments:

Post a Comment